Meredith WadmanScience’s COVID-19 reporting is supported by the Heising-Simons Foundation.The dark-horse vaccine company Novavax announced strong results today from a pivotal, 30,000-person trial of its pandemic coronavirus vaccine in the United States and Mexico.
The vaccine, which uses a different technology than the COVID-19 vaccines authorized so far, delivered 90.4% overall efficacy against symptomatic COVID-19 infections, and 100% protection against moderate and severe disease.
Against eight viral variants of interest and concern, its efficacy was 93.2%. And the vaccine appeared safe and well-tolerated.“This vaccine looks phenomenal.